what's trending

5 most popular innovation stories in Houston this week

Hit the highlights of Houston's innovation ecosystem with this roundup of trending news. Photo via Getty Images

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included Houston mayoral candidates weighing in on the tech ecosystem, a Houston startup raising funding, and more.

Gene therapy company breaks ground on Houston biomanufacturing facility

The new development will allow PackGene to nearly triple its Houston-area workforce by the end of the year when the facility is expected to be completed. Photo courtesy of PackGene

China-based and Massachusetts-founded PackGene Biotech Inc. broke ground last week on a new 25,000-square-foot biomanufacturing and processing facility just south of NRG Park.

The full-service operations center is slated to include labs, manufacturing clean rooms, warehouse, and office space. According to a release from the company, PackGene already employs about 20 people at an existing space in Houston. The new development will allow the company to nearly triple its Houston-area workforce by the end of the year when the facility is expected to be completed.

E&K Building Group is providing design-build services on the project, and the architect of record is Perkins + Will.

"These capabilities will enable us to serve our U.S. customers better and, importantly, to help bring life-saving therapies to patients faster, more reliably, and more cost- effectively. With this, we are making great strides in advancing our mission of 'making gene therapy affordable'," LiYing Yang, PackGene's CTO, says in a statement. Read more.

Overheard: Houston mayoral candidates share their platforms for the city's tech ecosystem

Three of Houston's mayoral candidates shared the stage at Tech Rodeo to talk about how they would lead the city toward greater success within the innovation space. Photo by Natalie Harms/InnovationMap

It's an election year in Houston, and one of the big topics on the minds of the candidates is how to continue the momentum of Houston's developing innovation ecosystem.

Houston Exponential put three of the declared candidates on the stage yesterday to ask them about their vision for Houston on the final day of Houston Tech Rodeo 2023. HX CEO Natara Branch moderated the discussion with Chris Hollins, Lee Kaplan, and Amanda K. Edwards. Each candidate addressed issues from diversity and equity, the energy transition, and more. Read more.

Prestigious Houston hospital system named No. 1 large employer in Texas and No. 2 in U.S. by Forbes

Heath care organizations made up 20 percent of the top 100 employers on Forbes' list. Photo via houstonmethodist.org

Attention to all those seeking a career in the medical industry: this top city hospital is one of the best places to work for. Houston Methodist was named the best large employer in Texas, and second best employer in America, according to Forbes’ latest report.

Health care organizations are the shining stars in this year’s report; they represented 20 percent of the top 100 employers. Houston Methodist made some major improvements within the span of a year after being ranked No. 37 in Forbes' 2022 report. In another win for health care, Dallas’ University of Texas Southwestern Medical Center was placed at No. 19.

To determine their rankings, Forbes partnered with consumer data and statistics firm Statista to survey 45,000 employees at companies with a staff of 5,000 or more. The full list categorized 500 of America’s large employers that earned the most recommendations. Read more.

Houston restaurant tech now serving optimized mobile ordering

This new restaurant technology allows for eateries to upgrade to mobile ordering for no cost. Photo courtesy of Cloche

A new Houston company has designed a platform that enables mobile ordering at no cost to restaurants.

Cloche, a mobile software platform named after the bell-shape dish cover that's known to come with room service orders, has launched in Houston and is currently looking for restaurants interested in utilizing their technology to upgrade their eatery with mobile ordering at no cost to the restaurant.

Alfredo Arvide, co-founder and managing director, tells InnovationMap that the idea for the platform came after the pandemic forced restaurateurs to quickly pivot to touch-free menus. Now that the consumer has adapted to scanning QR codes to view menus, the next step is to optimize ordering — something that will also help with the labor shortages that restaurants are now facing.

"Now is the time transform this industry by creating a better meal experience for the consumers, an easier job for the restaurant staff and a more efficient, more profitable business for restaurant owners," Arvide says. Read more.

Houston health tech company closes $3M series A

Prana Thoracic, an innovative startup in the lung cancer diagnostics space, has raised its series A round of investment. Photo via LinkedIn

It's been just under six months since the launch of Prana Thoracic, a Houston health tech startup tackling lung cancer diagnostics, and the company has already secured its next round of investment funding.

Prana Thoracic, a medical device company developing a tool for early interception of lung cancer, announced last week that it closed a $3 million series A financing round led by Florida-based New World Angels with participation from Johnson & Johnson Innovation – JJDC, Inc., Texas Medical Center Venture Fund, and the University City Science Center’s Phase 1 Ventures.

In August, the company received a $3 million award from the Cancer Prevention & Research Institute of Texas. All of Prana Thoracic's funding is being used to develop the unique diagnostic product and the company's path to first-in-human clinical studies.

“Our technology provides a definitive answer to patients with lung nodules and allows physicians to intervene earlier in the lung cancer patient’s journey,” says Joanna Nathan, CEO, and co-founder of Prana, in a news release. “Our team is grateful to have the support of our investors and excited to leverage this financing to accelerate our technology to the bedside.” Read more.

Trending News

 
 

Promoted

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Trending News

 
 

Promoted